STAT3 and cancer: Inhibition of oncogenic transcription factors is the object of two ongoing trials, aimed at testing the siRNA-mediated inhibition of c-Myc in multiple solid tumors or hepatocellular carcinoma, and seven clinical trials dealing with Stat3-targeted ASOs in advanced cancers [110].